Evidence map›Paper›PMID 35550625›Full record

ArticleAlzheimer's research & therapy2022

β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.

Tao-Ran Li, Yun-Xia Yao, Xue-Yan Jiang, Qiu-Yue Dong, Xian-Feng Yu, Ting Wang, Yan-Ning Cai, Ying Han

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Prospects and challenges in using neuronal extracellular vesicles in biomarker research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tao-Ran LiDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Yun-Xia YaoDepartment of Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Xue-Yan JiangDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Qiu-Yue DongKey Laboratory of Specialty Fiber Optics and Optical Access Networks, Joint International Research Laboratory of Specialty Fiber Optics and Advanced Communication, School of Information and Communication Engineering, Shanghai University, Shanghai, 200444, China.
Xian-Feng YuDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Ting WangDepartment of Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Yan-Ning CaiDepartment of Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China. caiyanning@xwh.ccmu.edu.cn.
Ying HanDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China. hanying@xwh.ccmu.edu.cn.ORCID 0000-0003-0377-7424
Capital Medical University · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBlood biomarkers that can be used for preclinical Alzheimer's disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible. Here, we investigated plasma neuronal-derived extracellular vesicle (nEV) cargo in patients along the Alzheimer's continuum, focusing on cognitively normal controls (NCs) with high brain β-amyloid (Aβ) loads (Aβ+).

methodsThe study was based on the Sino Longitudinal Study on Cognitive Decline project. We enrolled 246 participants, including 156 NCs, 45 amnestic mild cognitive impairment (aMCI) patients, and 45 AD dementia (ADD) patients. Brain Aβ loads were determined using positron emission tomography. NCs were classified into 84 Aβ- NCs and 72 Aβ+ NCs. Baseline plasma nEVs were isolated by immunoprecipitation with an anti-CD171 antibody. After verification, their cargos, including Aβ, tau phosphorylated at threonine 181, and neurofilament light, were quantified using a single-molecule array. Concentrations of these cargos were compared among the groups, and their receiver operating characteristic (ROC) curves were constructed. A subset of participants underwent follow-up cognitive assessment and magnetic resonance imaging. The relationships of nEV cargo levels with amyloid deposition, longitudinal changes in cognition, and brain regional volume were explored using correlation analysis. Additionally, 458 subjects in the project had previously undergone plasma Aβ quantification.

resultsOnly nEV Aβ was included in the subsequent analysis. We focused on Aβ

conclusionsOur findings suggest the potential use of plasma nEV Aβ

Indexed as

Alzheimer DiseaseAmyloidosisCognitive DysfunctionExtracellular VesiclesAdultAmyloid beta-PeptidesBiomarkersHumansPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseaseAβBlood biomarkerExtracellular vesiclenEVsPreclinical AD

Identifiers

PMID35550625
PMCPMC9097146
OpenAlexW4280576171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.